7-Year Outcomes of Balloon-Expandable Versus Self-Expanding Valves in Women Undergoing Transcatheter Aortic Valve Replacement Authors: Juri Iwata, Masanori Yamamoto, Kei Kamata, Ryo Arita, Tomonari Moriizumi, Toshinobu Ryuzaki, Hikaru Tsuruta, Takahiro Tokuda, Shinichi Shirai, Yusuke Watanabe, Toru Naganuma, Futoshi Yamanaka, Masahiko Noguchi, Yohei Ohno, Masaki Izumo, Hidetaka Nishina, Masahiko Asami, Gaku Nakazawa, Fumiaki Yashima, Hirofumi Hioki, Tetsuro Shimura, Kenichi Ishizu, Yasushi Fuku, Toshiaki Otsuka, Hideyuki Shimizu, Masaki Ieda, Kentaro Hayashida, OCEAN-TAVI Investigators Published: 2026 ABSTRACT BackgroundFemale patients with aortic stenosis frequently present with a small aortic annulus (SAA), which may result in unfavorable echocardiographic cardiac function after transcatheter aortic valve replacement. However, evidence comparing the long-term outcomes of balloon-expandable valves (BEVs) and self-expanding valves (SEVs) in this context is limited.ObjectivesThis study compares the 7-year clinical outcomes after transcatheter aortic valve replacement using BEV and SEV in female patients.MethodsOverall, 1,827 female patients treated with BEV and 805 treated with SEV were identified from the Optimized transCathEter vAlvular intervention-Transcatheter Aortic Valve Implantation (OCEAN-TAVI) registry. One-to-one propensity score matching (PSM) was performed to adjust for confounding factors, resulting in 744 matched patients per group. The primary clinical endpoints included all-cause mortality, stroke, and heart failure rehospitalization.ResultsOverall, 1,303 patients (87.6%) had a SAA. Echocardiographic assessments indicated that BEV had smaller effective orifice area and higher mean pressure gradient than did SEV throughout the follow-up period. In the PSM analysis, BEV was associated with lower all-cause mortality (51.5% vs 57.4%; log-rank, P = 0.021) and stroke at 7 years (10.8% vs 16.7%; Fine-Gray, P = 0.008). Heart failure rehospitalization rates were similar between groups. In multivariable analyses, valve type was not independently associated with long-term outcomes, and subgroup analyses considering annulus size yielded consistent results.ConclusionsFor women predominantly presenting with a SAA, BEV demonstrated decreased echocardiac performance compared with SEV. Although PSM analysis indicated more favorable outcomes with BEV, valve type was not independently associated with long-term prognosis after multivariable adjustment. These findings suggest that both types of transcatheter heart valves may be an acceptable option in this patient population. The excellent clinical outcomes of transcatheter aortic valve replacement (TAVR) for the short to mid-term are well established,1, 2, 3, 4 and the indications for TAVR are rapidly expanding to include younger and lower-risk patients with aortic stenosis. Consequently, understanding the clinical characteristics, durability, and long-term outcomes of each type of transcatheter heart valve (THV) has become increasingly important. Recent studies, including a pivotal randomized controlled trial, have demonstrated better echocardiography-derived profiles of self-expanding valves (SEVs) those of balloon-expandable valves (BEVs) in patients with a small aortic annulus (SAA).5, 6, 7 This issue is particularly pertinent for women who frequently have a SAA and are more likely to experience prosthesis-patient mismatch (PPM) and elevated transvalvular pressure gradients (PGs) when treated with BEV and SEV.8, 9, 10, 11 Although the type of valve contributes to these findings, echocardiographic data suggest that women tend to exhibit suboptimal performance after TAVR. Given these observations, poorer outcomes in women may be anticipated. However, despite these disadvantages of echocardiac assessment, studies have reported that female patients experience better survival rates after TAVR than do their male counterparts.12, 13, 14, 15 This paradox raises significant questions regarding the extent to which unfavorable echocardiographic findings correlate with inferior long-term outcomes in women. Consequently, we conducted this study to evaluate the durability and long-term clinical outcomes of BEV and SEV, specifically among women predominantly presenting with a SAA, using data from a nationwide registry. Methods Study cohort The OCEAN-TAVI (Optimized transCathEter vAlvular intervention-Transcatheter Aortic Valve Implantation) registry is an ongoing nationwide prospective multicenter cohort study involving patients with aortic stenosis undergoing TAVR at 22 collaborating centers across Japan. This analysis retrospectively included patients who underwent TAVR with BEV or SEV between October 2013 and September 2019 at the participating institutes. Male patients and those who underwent TAVR for degenerated surgical bioprostheses or THV were excluded. Participating centers were required to enroll patients in the registry, comply with the registry protocol, and submit patient information and clinical outcomes during follow-up. The study protocol received approval from the ethics committee at each center, and all patients provided written informed consent for their participation. This study was conducted in accordance with the principles of the Declaration of Helsinki. In addition, the study was registered with the University Hospital Medical Information Network Clinical Trials Registry and was accepted by the International Committee of Medical Journal Editors (UMINID000020423). Data collection and endpoint definitions Baseline clinical, procedural, and follow-up data were prospectively recorded in a web-based database at each participating center. Regular follow-up appointments were scheduled before the procedure, at discharge, 1 month postprocedure, and annually thereafter after TAVR. Comprehensive clinical follow-up data were collected from medical records at each center, documentation from referring physicians, and/or telephone interviews. The web-based database was systematically audited by members of the data committee to ensure its completeness and accuracy, thereby ensuring data integrity. In instances of incomplete or inaccurate data, all participating centers were required to respond to queries. Transthoracic echocardiography was performed before TAVR, at discharge, and annually thereafter. Following the updated Valve Academic Research Consortium-3 (VARC-3) criteria,1 PPM was evaluated on the basis of the effective orifice area (EOA) indexed to body surface area. PPM was categorized as severe (≤0.65 cm2/m2 in the population without obesity [body mass index <30 kg/m2]; ≤0.55 cm2/m2 in the population with obesity [body mass index ≥30 kg/m2]) or moderate (>0.65-0.85 cm2/m2 in the population without obesity; >0.55-0.70 cm2/m2 in the population with obesity). All procedural complications were classified according to the Valve Academic Research Consortium-3 criteria,16 and relevant data were systematically collected. The clinical endpoints included all-cause mortality, stroke, and heart failure rehospitalization (HFH). Statistical analysis Categorical variables were reported as frequency and percentage, with differences evaluated using the chi-square test or the 2-tailed Fisher exact test, as appropriate. Continuous variables were presented as mean ± SD or median (Q1-Q3), with between-group comparisons conducted using the 2-sample Student’s t-test or the Mann-Whitney U test, as appropriate. Time-to-event curves were illustrated using the Kaplan-Meier method, with censoring at death or the last valid contact for cases involving patients awaiting the next follow-up or withdrawal of consent. Despite rigorous queries performed at each center, missing values that could not be eliminated were analyzed using the multiple imputation method. A Cox proportional hazards model was used to calculate HRs and 95% CIs for all-cause mortality. In addition, a Fine-Gray model was used to compute HRs and 95% CIs for stroke and HFH. All P values were 2-sided, with a P value <0.05 deemed significant for all tests. Statistical analyses were performed using SPSS version 29 (IBM Corporation). We used propensity score matching (PSM) to control for confounding factors arising from baseline differences between patients undergoing TAVR with BEV and SEV. The propensity score was calculated using a multivariable logistic regression model based on 25 variables that could potentially influence study outcomes: age, body mass index (kg/m2), Society of Thoracic Surgeons (STS)–predicted risk of mortality (%), clinical frailty scale (CFS) ≥4, NYHA functional class III or IV, hypertension, diabetes mellitus, peripheral artery disease, chronic obstructive pulmonary disease, atrial fibrillation, estimated glomerular filtration rate (mL/min per 1.73 m2), hemoglobin level (g/dL), history of coronary artery disease, history of stroke, previous pacemaker implantation, echocardiographic variables (including index aortic valve area [cm2/m2], aortic valve mean PG [mm Hg], left ventricular ejection fraction [%], and moderate or severe aortic, mitral, tricuspid regurgitation, respectively), computed tomography variables (such as annulus area [mm2], annulus perimeter [mm], and presence or absence of calcification in the left ventricular outflow tract), and procedural variables (including access site: transfemoral approach or alternative). A 1:1 greedy nearest-neighbor matching protocol with a caliper of 0.2 was implemented. Absolute standardized differences were calculated for all baseline variables, with differences of <0.10 indicating good balance. Results for the overall matched cohort and cohorts based on annulus size were analyzed. In addition, for the overall cohort before PSM, we performed multivariable logistic regression models adjusted for variables that were significant in the univariable analysis, and we also performed inverse probability of treatment weighting analysis as a sensitivity analysis. Results Study population and baseline characteristics Of the 5,237 patients who underwent TAVR with BEV and SEV, 1,827 and 805 met the inclusion criteria, respectively, and were included herein. One-to-one PSM resulted in 744 patients in each of the BEV and SEV groups (Figure 1). The baseline characteristics of the unmatched and matched cohorts are presented in Table 1. Before PSM, the groups differed in several parameters, including CFS and other comorbidities. The BEV group was younger (84.7 ± 5.2 cm2 vs 85.1 ± 4.9 cm2; P = 0.024) and had a larger body mass index (22.3 ± 3.9 kg/m2 vs 21.7 ± 3.9 kg/m2; P < 0.001), a lower STS score (6.0% [4.3%-8.9%] vs 6.9% [4.9%-9.7%]; P < 0.001), a lower incidence of chronic obstructive pulmonary disease (3.9% vs 6.8%; P = 0.001), and peripheral artery disease (9.0% vs 13.4%; P < 0.001). In echocardiographic assessments, patients in the BEV group exhibited a larger aortic valve area (0.61 ± 0.17 cm2 vs 0.58 ± 0.19 cm2; P < 0.001) and a larger index aortic valve area (0.45 ± 0.13 cm2/m2 vs 0.43 ± 0.13 cm2/m2; P = 0.001) than did those in the SEV group. In computed tomography analysis, the BEV group had a larger annulus area (380 ± 55 mm2 vs 362 ± 59 mm2; P < 0.001), a longer perimeter (70.0 ± 6.1 mm vs 58.7 ± 5.8 mm; P < 0.001), and a lower presence of left ventricular outflow tract calcification (16.1% vs 29.3%; P < 0.001). After PSM, patient characteristics of the BEV and SEV groups were well balanced, with absolute standardized differences <0.10 across most of the measured baseline characteristics except for the STS score (0.118) and transfemoral approach (0.123).Figure 1Study FlowchartOf the 5,237 patients who underwent transcatheter aortic valve replacement with BEV or SEV between October 2013 and September 2019, 1,827 and 805 met the inclusion criteria, respectively. One-to-one PS matching resulted in 744 patients in each of the BEV and SEV groups. BEV = balloon-expandable valve; OCEAN-TAVI = Optimized transCathEter vAlvular intervention-Transcatheter Aortic Valve Implantation; PS = propensity score; SAV = surgical aortic valve; SEV = self-expanding valve; TAV = transcatheter aortic valve.Table 1Baseline Characteristics of the Prematched and Matched CohortsPrematched CohortMatched CohortASDBEV (n = 1,827)SEV (n = 805)P ValueBEV (n = 744)SEV (n = 744)P ValueAge, y84.7 ± 5.285.1 ± 4.90.02484.7 ± 5.285.0 ± 4.90.3880.057Body mass index, kg/m222.3 ± 3.921.7 ± 3.9<0.00121.7 ± 3.921.7 ± 3.80.8640.010STS score, %6.0 (4.3-8.9)6.9 (4.9-9.7)<0.0015.7 (4.2-8.5)6.8 (4.9-9.5)<0.0010.118Clinical frailty scale ≥ 41,079 (59.1)505 (62.7)0.171448 (60.2)464 (62.4)0.3940.044NYHA functional class III or IV670 (36.7)301 (37.4)0.725294 (39.5)270 (36.3)0.2000.066Hemoglobin, g/dL11.2 (10.2-12.2)11.1 (10.1-12.0)0.09711.2 (10.1-12.2)11.2 (10.1-12.1)0.5220.043Brain natrium peptide, pg/mL192 (94-438)254 (116-541)<0.001250 (115-510)251 (114-535)0.8250.103Concomitant diseases Hypertension1,540 (84.3)690 (85.7)0.350639 (85.9)633 (85.1)0.6590.023 Diabetes mellitus490 (26.8)220 (27.3)0.768204 (27.4)204 (27.4)1.0000 Dyslipidemia1,060 (58.0)472 (58.6)0.768434 (58.3)440 (59.1)0.7520.016 Chronic kidney disease (estimated GFR <60 mL/min per 1.73 m2)1,289 (70.6)567 (70.4)0.951525 (70.6)522 (70.2)0.8650.009 Estimated GFR, mL/min per 1.73 m251.1 ± 18.550.6 ± 18.90.52951.6 ± 18.651.3 ± 18.20.9920.016 Chronic obstructive pulmonary disease71 (3.9)55 (6.8)0.00143 (5.8)41 (5.5)0.8220.012 Atrial fibrillation398 (20.7)176 (21.9)0.500161 (21.6)154 (20.7)0.6570.023 Coronary artery disease539 (29.5)216 (26.8)0.163194 (26.1)196 (26.3)0.9060.006 Peripheral artery disease164 (9.0)108 (13.4)<0.00187 (11.7)91 (12.2)0.7490.017 Carotid stenosis58 (6.5)69 (4.7)0.05025 (3.4)40 (5.4)0.0990.103Previous history Smoking50 (2.8)27 (3.4)0.38427 (3.6)25 (3.4)0.1450.013 History of percutaneous coronary intervention359 (19.6)150 (18.6)0.543134 (18.0)138 (18.5)0.7880.014 History of coronary artery bypass grafting48 (2.6)26 (3.2)0.38913 (1.7)23 (3.1)0.0920.088 History of myocardial infarction76 (4.2)30 (3.7)0.60326 (3.5)28 (3.8)0.7820.014 History of stroke188 (10.3)95 (11.8)0.24990 (12.1)87 (11.7)0.810.012 Previous pacemaker87 (4.8)45 (5.6)0.53840 (5.4)40 (5.4)1.0000Echocardiographic data Aortic valve area, cm20.61 ± 0.170.58 ± 0.19<0.0010.58 ± 0.160.59 ± 0.190.9640.024 Index aortic valve area, cm2/m20.45 ± 0.130.43 ± 0.130.0010.43 ± 0.120.43 ± 0.140.960.027 Peak flow velocity, m/s4.5 ± 0.794.7 ± 0.87<0.0014.6 ± 0.824.7 ± 0.860.2040.082 Aortic valve peak gradient, mm Hg84.2 ± 29.092.0 ± 33.8<0.00188.8 ± 31.391.6 ± 33.30.2040.088 Aortic valve mean gradient, mm Hg49.0 ± 18.052.8 ± 21.2<0.00152.2 ± 19.452.5 ± 20.80.7570.014 Left ventricular ejection fraction, %61.4 ± 11.961.9 ± 11.20.26163.1 ± 11.662.0 ± 11.10.0360.096 Aortic regurgitation ≥ moderate166 (9.1)77 (9.6)0.48071 (9.5)69 (9.3)0.8590.009 Mitral regurgitation ≥ moderate262 (14.3)117 (14.5)0.639109 (14.7)101 (13.6)0.5510.031 Tricuspid regurgitation ≥ moderate170 (9.3)80 (9.9)0.56764 (8.6)76 (10.2)0.2870.055Computed tomography data Annulus area, mm2380 ± 55362 ± 59<0.001369 ± 52364 ± 590.1690.075 Annulus perimeter, mm70.0 ± 6.158.7 ± 5.8<0.00169.3 ± 4.968.8 ± 5.80.2460.083 LVOT calcification289 (16.1)236 (29.3)<0.001180 (24.2)197 (26.5)0.3110.052Values are mean ± SD, median (Q1-Q3), or n (%). P values are from the Fisher exact test (2 × 2 comparison), chi-square test (2 × 2 comparisons), or Student’s t test (continuous parameters).ASD = absolute standardized difference; BEV = balloon-expandable valve; GFR = glomerular filtration rate; LVOT = left ventricular outflow tract; SEV = self-expanding valve; STS = Society of Thoracic Surgeons. Study Flowchart Of the 5,237 patients who underwent transcatheter aortic valve replacement with BEV or SEV between October 2013 and September 2019, 1,827 and 805 met the inclusion criteria, respectively. One-to-one PS matching resulted in 744 patients in each of the BEV and SEV groups. BEV = balloon-expandable valve; OCEAN-TAVI = Optimized transCathEter vAlvular intervention-Transcatheter Aortic Valve Implantation; PS = propensity score; SAV = surgical aortic valve; SEV = self-expanding valve; TAV = transcatheter aortic valve. Table 1Baseline Characteristics of the Prematched and Matched CohortsPrematched CohortMatched CohortASDBEV (n = 1,827)SEV (n = 805)P ValueBEV (n = 744)SEV (n = 744)P ValueAge, y84.7 ± 5.285.1 ± 4.90.02484.7 ± 5.285.0 ± 4.90.3880.057Body mass index, kg/m222.3 ± 3.921.7 ± 3.9<0.00121.7 ± 3.921.7 ± 3.80.8640.010STS score, %6.0 (4.3-8.9)6.9 (4.9-9.7)<0.0015.7 (4.2-8.5)6.8 (4.9-9.5)<0.0010.118Clinical frailty scale ≥ 41,079 (59.1)505 (62.7)0.171448 (60.2)464 (62.4)0.3940.044NYHA functional class III or IV670 (36.7)301 (37.4)0.725294 (39.5)270 (36.3)0.2000.066Hemoglobin, g/dL11.2 (10.2-12.2)11.1 (10.1-12.0)0.09711.2 (10.1-12.2)11.2 (10.1-12.1)0.5220.043Brain natrium peptide, pg/mL192 (94-438)254 (116-541)<0.001250 (115-510)251 (114-535)0.8250.103Concomitant diseases Hypertension1,540 (84.3)690 (85.7)0.350639 (85.9)633 (85.1)0.6590.023 Diabetes mellitus490 (26.8)220 (27.3)0.768204 (27.4)204 (27.4)1.0000 Dyslipidemia1,060 (58.0)472 (58.6)0.768434 (58.3)440 (59.1)0.7520.016 Chronic kidney disease (estimated GFR <60 mL/min per 1.73 m2)1,289 (70.6)567 (70.4)0.951525 (70.6)522 (70.2)0.8650.009 Estimated GFR, mL/min per 1.73 m251.1 ± 18.550.6 ± 18.90.52951.6 ± 18.651.3 ± 18.20.9920.016 Chronic obstructive pulmonary disease71 (3.9)55 (6.8)0.00143 (5.8)41 (5.5)0.8220.012 Atrial fibrillation398 (20.7)176 (21.9)0.500161 (21.6)154 (20.7)0.6570.023 Coronary artery disease539 (29.5)216 (26.8)0.163194 (26.1)196 (26.3)0.9060.006 Peripheral artery disease164 (9.0)108 (13.4)<0.00187 (11.7)91 (12.2)0.7490.017 Carotid stenosis58 (6.5)69 (4.7)0.05025 (3.4)40 (5.4)0.0990.103Previous history Smoking50 (2.8)27 (3.4)0.38427 (3.6)25 (3.4)0.1450.013 History of percutaneous coronary intervention359 (19.6)150 (18.6)0.543134 (18.0)138 (18.5)0.7880.014 History of coronary artery bypass grafting48 (2.6)26 (3.2)0.38913 (1.7)23 (3.1)0.0920.088 History of myocardial infarction76 (4.2)30 (3.7)0.60326 (3.5)28 (3.8)0.7820.014 History of stroke188 (10.3)95 (11.8)0.24990 (12.1)87 (11.7)0.810.012 Previous pacemaker87 (4.8)45 (5.6)0.53840 (5.4)40 (5.4)1.0000Echocardiographic data Aortic valve area, cm20.61 ± 0.170.58 ± 0.19<0.0010.58 ± 0.160.59 ± 0.190.9640.024 Index aortic valve area, cm2/m20.45 ± 0.130.43 ± 0.130.0010.43 ± 0.120.43 ± 0.140.960.027 Peak flow velocity, m/s4.5 ± 0.794.7 ± 0.87<0.0014.6 ± 0.824.7 ± 0.860.2040.082 Aortic valve peak gradient, mm Hg84.2 ± 29.092.0 ± 33.8<0.00188.8 ± 31.391.6 ± 33.30.2040.088 Aortic valve mean gradient, mm Hg49.0 ± 18.052.8 ± 21.2<0.00152.2 ± 19.452.5 ± 20.80.7570.014 Left ventricular ejection fraction, %61.4 ± 11.961.9 ± 11.20.26163.1 ± 11.662.0 ± 11.10.0360.096 Aortic regurgitation ≥ moderate166 (9.1)77 (9.6)0.48071 (9.5)69 (9.3)0.8590.009 Mitral regurgitation ≥ moderate262 (14.3)117 (14.5)0.639109 (14.7)101 (13.6)0.5510.031 Tricuspid regurgitation ≥ moderate170 (9.3)80 (9.9)0.56764 (8.6)76 (10.2)0.2870.055Computed tomography data Annulus area, mm2380 ± 55362 ± 59<0.001369 ± 52364 ± 590.1690.075 Annulus perimeter, mm70.0 ± 6.158.7 ± 5.8<0.00169.3 ± 4.968.8 ± 5.80.2460.083 LVOT calcification289 (16.1)236 (29.3)<0.001180 (24.2)197 (26.5)0.3110.052Values are mean ± SD, median (Q1-Q3), or n (%). P values are from the Fisher exact test (2 × 2 comparison), chi-square test (2 × 2 comparisons), or Student’s t test (continuous parameters).ASD = absolute standardized difference; BEV = balloon-expandable valve; GFR = glomerular filtration rate; LVOT = left ventricular outflow tract; SEV = self-expanding valve; STS = Society of Thoracic Surgeons. Baseline Characteristics of the Prematched and Matched Cohorts Values are mean ± SD, median (Q1-Q3), or n (%). P values are from the Fisher exact test (2 × 2 comparison), chi-square test (2 × 2 comparisons), or Student’s t test (continuous parameters). ASD = absolute standardized difference; BEV = balloon-expandable valve; GFR = glomerular filtration rate; LVOT = left ventricular outflow tract; SEV = self-expanding valve; STS = Society of Thoracic Surgeons. Procedural characteristics, complications, and echocardiographic outcomes The procedures, complications, and echocardiographic outcomes of the prematched and matched cohorts are presented in Table 2. The BEV group underwent a lower rate of local anesthesia (269 (36.2%) vs 466 (62.6%); P < 0.001) and predilatation (319 (42.9%) vs 544 (73.1%); P < 0.001). Regarding in-hospital clinical outcomes, the rates of life-threatening and major bleeding, disabling stroke, and new pacemaker implantation were significantly lower in the BEV group than in the SEV group (49 (6.6%) vs 71 (9.5%), P = 0.036; 5 (5 (0.7%)) vs 15 (15 (2.0%)), P = 0.024; and 58 (7.8%) vs 87 (11.7%), P = 0.011, respectively). Postprocedural echocardiography revealed a smaller EOA (1.46 ± 0.38 cm2 vs 1.68 ± 0.42 cm2; P < 0.001), a smaller index EOA (1.08 ± 0.28 cm2/m2 vs 1.14 ± 0.30 cm2/m2; P < 0.001), a higher peak flow velocity (2.4 ± 0.45 m/s vs 2.1 ± 0.47 m/s; P < 0.001), and a higher mean PG (12.9 ± 5.1 mm Hg vs 8.8 ± 4.6 mm Hg, P < 0.001; and mean PG ≥20 mm Hg: 71 (9.5%) vs 19 (2.6%), P < 0.001) in the BEV group than in the SEV group (Figure 2). Patients in the BEV group had a higher incidence of PPM (P < 0.001) but a lower incidence of paravalvular leakage (P < 0.001) than did those in the SEV group. The prevalence of NYHA functional class III or IV at discharge was significantly higher in the BEV group than in the SEV group (29 (3.9%) vs 14 (1.9%); P < 0.001).Table 2Procedures, Complications, and Echocardiographic OutcomesPrematched CohortMatched CohortBEV (n = 1,827)SEV (n = 805)P ValueBEV (n = 744)SEV (n = 744)P ValueTransfemoral1,684 (92.2)729 (90.6)0.167652 (87.6)680 (91.4)0.018Valve size 20 mm177 (9.7)–99 (13.3)– 23 mm1,327 (72.6)160 (19.9)554 (74.5)145 (19.5) 26 mm310 (17.0)504 (62.6)88 (11.8)463 (62.2) 29 mm13 (0.7)141 (17.5)3 (0.4)136 (18.3)Local anesthesia1,018 (55.7)493 (61.2)0.008269 (36.2)466 (62.6)<0.001Predilatation720 (39.4)588 (73.0)<0.001319 (42.9)544 (73.1)<0.001Postdilatation391 (21.4)145 (18.0)0.046137 (18.4)129 (17.3)0.580Echocardiographic data Effective orifice area, cm21.53 ± 0.391.67 ± 0.42<0.0011.46 ± 0.381.68 ± 0.42<0.001 Index effective orifice area, cm2/m21.11 ± 0.291.24 ± 0.33<0.0011.08 ± 0.281.14 ± 0.30<0.001 Peak flow velocity, m/s2.4 ± 0.442.1 ± 0.48<0.0012.4 ± 0.452.1 ± 0.47<0.001 Mean pressure gradient, mm Hg12.8 ± 4.98.9 ± 4.7<0.00112.9 ± 5.18.8 ± 4.6<0.001 Mean pressure gradient ≥20 mm Hg158 (8.6)23 (2.9)<0.00171 (9.5)19 (2.6)<0.001 Prosthesis-patient mismatch20 (2.3)132 (5.5)<0.001 None1,505 (82.4)699 (86.8)595 (80.0)648 (87.1)<0.001 Moderate256 (14.0)71 (8.8)120 (16.1)67 (9.0) Severe41 (2.2)10 (1.2)20 (2.7)9 (1.2) Paravalvular leakage ≥ mild418 (22.9)327 (40.6)<0.001183 (24.6)301 (40.5)<0.001 Paravalvular leakage None465 (25.5)175 (21.7)<0.00128 (28.0)158 (21.2)<0.001 Trivial944 (51.7)302 (37.5)353 (47.4)284 (38.2) Mild402 (22.0)295 (36.6)172 (23.1)273 (36.7) Moderate16 (0.9)32 (4.0)11 (1.5)28 (3.8) Severe0 (0)0 (0)0 (0)0 (0)Mitral regurgitation ≥ moderate191 (10.5)76 (9.4)0.22191 (12.2)70 (9.4)0.129Tricuspid regurgitation ≥ moderate167 (9.1)81 (10.1)0.11981 (10.9)76 (10.2)0.521Ent days7 (5-11)8 (6-11)0.0018 (6-12)8 (6-11)0.701In-hospital death19 (1.0)16 (2.0)0.0517 (0.9)13 (1.7)0.177Open surgery13 (0.7)5 (0.6)0.7956 (0.8)5 (0.7)0.762Coronary obstruction11 (0.6)5 (0.6)0.9543 (0.4)5 (0.7)0.478Life-threatening and major bleeding122 (6.7)77 (9.6)0.01049 (6.6)71 (9.5)0.036Disabling stroke15 (0.8)16 (2.0)0.0115 (0.7)15 (2.0)0.024Major vascular complication71 (3.9)41 (5.1)0.15726 (3.5)34 (4.6)0.292Tamponade18 (1.0)7 (0.9)0.77810 (1.3)6 (0.8)0.315New pacemaker implantation128 (7.0)94 (11.7)<0.00158 (7.8)87 (11.7)0.011NYHA functional class III or IV at discharge48 (2.6)14 (1.7)0.04929 (3.9)14 (1.9)<0.001Values are mean ± SD or n (%). P values are from the chi-square test (n × 2 comparisons) or Student’s t-test (continuous parameters).Abbreviations as in Table 1.Figure 2Echocardiography After Transcatheter Aortic Valve Replacement: Comparing BEV and SEVThis figure summarizes the comparison of echocardiographic assessments at discharge and at 1, 5, 6, and 7 years after transcatheter aortic valve replacement in patients with BEV and those with SEV. (A) Paravalvular leakage. (B) Index effective orifice area. (C) Mean pressure gradient. Abbreviations as in Figure 1. Table 2Procedures, Complications, and Echocardiographic OutcomesPrematched CohortMatched CohortBEV (n = 1,827)SEV (n = 805)P ValueBEV (n = 744)SEV (n = 744)P ValueTransfemoral1,684 (92.2)729 (90.6)0.167652 (87.6)680 (91.4)0.018Valve size 20 mm177 (9.7)–99 (13.3)– 23 mm1,327 (72.6)160 (19.9)554 (74.5)145 (19.5) 26 mm310 (17.0)504 (62.6)88 (11.8)463 (62.2) 29 mm13 (0.7)141 (17.5)3 (0.4)136 (18.3)Local anesthesia1,018 (55.7)493 (61.2)0.008269 (36.2)466 (62.6)<0.001Predilatation720 (39.4)588 (73.0)<0.001319 (42.9)544 (73.1)<0.001Postdilatation391 (21.4)145 (18.0)0.046137 (18.4)129 (17.3)0.580Echocardiographic data Effective orifice area, cm21.53 ± 0.391.67 ± 0.42<0.0011.46 ± 0.381.68 ± 0.42<0.001 Index effective orifice area, cm2/m21.11 ± 0.291.24 ± 0.33<0.0011.08 ± 0.281.14 ± 0.30<0.001 Peak flow velocity, m/s2.4 ± 0.442.1 ± 0.48<0.0012.4 ± 0.452.1 ± 0.47<0.001 Mean pressure gradient, mm Hg12.8 ± 4.98.9 ± 4.7<0.00112.9 ± 5.18.8 ± 4.6<0.001 Mean pressure gradient ≥20 mm Hg158 (8.6)23 (2.9)<0.00171 (9.5)19 (2.6)<0.001 Prosthesis-patient mismatch20 (2.3)132 (5.5)<0.001 None1,505 (82.4)699 (86.8)595 (80.0)648 (87.1)<0.001 Moderate256 (14.0)71 (8.8)120 (16.1)67 (9.0) Severe41 (2.2)10 (1.2)20 (2.7)9 (1.2) Paravalvular leakage ≥ mild418 (22.9)327 (40.6)<0.001183 (24.6)301 (40.5)<0.001 Paravalvular leakage None465 (25.5)175 (21.7)<0.00128 (28.0)158 (21.2)<0.001 Trivial944 (51.7)302 (37.5)353 (47.4)284 (38.2) Mild402 (22.0)295 (36.6)172 (23.1)273 (36.7) Moderate16 (0.9)32 (4.0)11 (1.5)28 (3.8) Severe0 (0)0 (0)0 (0)0 (0)Mitral regurgitation ≥ moderate191 (10.5)76 (9.4)0.22191 (12.2)70 (9.4)0.129Tricuspid regurgitation ≥ moderate167 (9.1)81 (10.1)0.11981 (10.9)76 (10.2)0.521Ent days7 (5-11)8 (6-11)0.0018 (6-12)8 (6-11)0.701In-hospital death19 (1.0)16 (2.0)0.0517 (0.9)13 (1.7)0.177Open surgery13 (0.7)5 (0.6)0.7956 (0.8)5 (0.7)0.762Coronary obstruction11 (0.6)5 (0.6)0.9543 (0.4)5 (0.7)0.478Life-threatening and major bleeding122 (6.7)77 (9.6)0.01049 (6.6)71 (9.5)0.036Disabling stroke15 (0.8)16 (2.0)0.0115 (0.7)15 (2.0)0.024Major vascular complication71 (3.9)41 (5.1)0.15726 (3.5)34 (4.6)0.292Tamponade18 (1.0)7 (0.9)0.77810 (1.3)6 (0.8)0.315New pacemaker implantation128 (7.0)94 (11.7)<0.00158 (7.8)87 (11.7)0.011NYHA functional class III or IV at discharge48 (2.6)14 (1.7)0.04929 (3.9)14 (1.9)<0.001Values are mean ± SD or n (%). P values are from the chi-square test (n × 2 comparisons) or Student’s t-test (continuous parameters).Abbreviations as in Table 1. Procedures, Complications, and Echocardiographic Outcomes Values are mean ± SD or n (%). P values are from the chi-square test (n × 2 comparisons) or Student’s t-test (continuous parameters). Abbreviations as in Table 1. Echocardiography After Transcatheter Aortic Valve Replacement: Comparing BEV and SEV This figure summarizes the comparison of echocardiographic assessments at discharge and at 1, 5, 6, and 7 years after transcatheter aortic valve replacement in patients with BEV and those with SEV. (A) Paravalvular leakage. (B) Index effective orifice area. (C) Mean pressure gradient. Abbreviations as in Figure 1. Follow-up echocardiographic and other clinical data are presented in Figure 2. They were available at 1 year for 1,126 of the 1,363 living patients (82.6%), at 5 years for 457 of 738 living patients (61.9%), at 6 years for 127 of 325 living patients (39.0%), and at 7 years for 23 of 120 living patients (19.2%). Patients in the BEV group showed a significantly smaller index EOA and a higher mean PG than did those in the SEV group at 1, 5, 6, and 7 years after TAVR (Figure 2). The paravalvular leakage grade was significantly lower in the BEV group than in the SEV group at discharge; however, no significant differences were observed between the BEV and SEV groups at 1 year and thereafter after TAVR. Long-term clinical outcomes The mean follow-up duration for living patients was 1,515 ± 749 days. Kaplan-Meier curves depicting the clinical outcomes by group are shown in Figure 3. The temporal trend of valve utilization rate is shown in Figure 4. Throughout the study period, long-term mortality occurred in 51.5% and 57.4% of patients in the BEV and SEV groups, respectively, with a tendency for it to be lower in the BEV group than in the SEV group (HR: 0.830; 95% CI: 0.705-0.976; P = 0.024). The incidence of stroke at 7 years was significantly lower in the BEV group than in the SEV group, respectively (10.8% vs 16.7%; log-rank, P = 0.006; HR: 0.811; 95% CI: 0.695-0.947; Fine-Gray: P = 0.008), but there was no significant difference in the incidence of HFH (BEV vs SEV: 21.2% vs 15.7%; log-rank, P = 0.007; HR: 0.466; 95% CI: 0.791-1.073; Fine-Gray, P = 0.290). Of the total 1,488 patients, 3 patients required aortic valve reintervention during the follow-up period. All 3 patients were in the BEV group. The details of the reintervention were as follows: 1 patient underwent second TAVR for THV dysfunction at 1,978 days, 1 patient underwent surgical aortic valve replacement for infective endocarditis, and the last patient underwent surgical biological valve replacement, including coronary artery bypass surgery.Figure 3Kaplan-Meier Curves Comparing 7-Year Clinical Outcomes for BEV and SEVThis figure presents the results of a 7-year survival analysis of the propensity score–matched cohorts. P values were calculated using the log-rank method for all-cause mortality, and the Fine-Gray method for stroke and heart failure rehospitalization. (A) All-cause mortality. (B) Stroke. (C) Heart failure rehospitalization. Abbreviations as in Figure 1.Figure 4Temporal Trend of Valve Utilization RateThis figure shows the temporal trend of the valve utilization rate of BEV or SEV from 2016 to 2019. Abbreviations as in Figure 1. Kaplan-Meier Curves Comparing 7-Year Clinical Outcomes for BEV and SEV This figure presents the results of a 7-year survival analysis of the propensity score–matched cohorts. P values were calculated using the log-rank method for all-cause mortality, and the Fine-Gray method for stroke and heart failure rehospitalization. (A) All-cause mortality. (B) Stroke. (C) Heart failure rehospitalization. Abbreviations as in Figure 1. Temporal Trend of Valve Utilization Rate This figure shows the temporal trend of the valve utilization rate of BEV or SEV from 2016 to 2019. Abbreviations as in Figure 1. In the PSM cohort, subgroup analyses were performed using a forest plot to evaluate differences in long-term outcomes between SEV and BEV across potential risk modifiers of all-cause mortality, including annulus size (area and perimeter), mean PG, PPM, paravalvular leakage, age, body surface area, CFS, and STS score. Significant interactions were observed for annulus area <430 mm2, median annulus area <362 mm2, age ≥75 years, and STS score ≥8%, as shown in Figure 5. We also analyzed all-cause mortality using multivariable analysis in the prematched overall cohort. In the multivariable analysis, factors significantly associated with all-cause mortality included age at the time of procedure, CFS ≥4, NYHA functional class III or IV, atrial fibrillation, peripheral artery disease, hemoglobin level, severe PPM, and paravalvular leakage ≥ mild. THV type (BEV vs SEV) was not independently associated with mortality (Table 3). We assessed collinearity of the covariates as the variance inflation factor, and all the factors were between 1.0 and 2.0, suggesting that there was no significant multicollinearity. Using the inverse probability of treatment weighting analysis as a sensitivity analysis, there were no significant differences in all-cause mortality, stroke, and HFH between patients with BEV and SEV (all-cause mortality, HR: 0.915, 95% CI: 0.757-1.106, P = 0.358; stroke, HR: 0.759, 95% CI: 0.547-1.052, P = 0.098; and HFH, HR: 0.864, 95% CI: 0.341-2.189, P = 0.758).Figure 5Subgroup Analysis of the Association Between Valve Type and 7-Year MortalityThis figure shows the subgroup analyses presented in the forest plot to evaluate differences in long-term outcomes between BEV and SEV across potential risk modifiers of all-cause mortality. BSA = body surface area; CFS = clinical frailty scale; mPG = mean pressure gradient; PPM = prosthesis-patient mismatch; PVL = paravalvular leakage; STS = Society of Thoracic Surgeons; other abbreviations as in Figure 1.Table 3PreMatched All-Cause MortalityUnivariable AnalysisMultivariable AnalysisHR95% CIP ValueHR95% CIP ValueAge1.0551.041-1.070<0.0011.0351.021-1.049<0.001Body mass index0.9270.910-0.944<0.0010.9920.977-1.0080.348Clinical frailty scale ≥41.6721.462-1.912<0.0011.1671.089-1.251<0.001NYHA functional class III or IV1.7531.546-1.988<0.0011.1911.115-1.272<0.001Diabetes mellitus1.0660.928-1.2250.368Atrial fibrillation1.4451.250-1.671<0.0011.1611.079-1.250<0.001Coronary artery disease1.0700.932-1.2280.338Peripheral artery disease1.5091.248-1.825<0.0011.1281.023-1.2430.015Previous stroke1.1970.980-1.460.078Chronic obstructive pulmonary disease1.3051.003-1.6980.0481.0980.961-1.2560.170STS score1.0100.999-1.0200.067Hemoglobin0.8080.774-0.843<0.0010.8520.815-0.891<0.001Left ventricular ejection fraction0.9880.983-0.993<0.0010.9990.994-1.0030.571Annulus area0.9990.998-1.0010.317Annulus perimeter1.0000.990-1.0110.955Self-expanding valve1.1981.046-1.3730.0091.0510.980-1.1270.165Severe prosthesis-patient mismatch1.2281.018-1.4820.0321.2661.048-1.5300.014Mean pressure gradient ≥20 mm Hg1.0450.827-1.3210.710Paravalvular leakage1.2081.057-1.3810.0061.0811.009-1.1580.027P values are from the Cox proportional hazards model.STS = Society of Thoracic Surgeons. Subgroup Analysis of the Association Between Valve Type and 7-Year Mortality This figure shows the subgroup analyses presented in the forest plot to evaluate differences in long-term outcomes between BEV and SEV across potential risk modifiers of all-cause mortality. BSA = body surface area; CFS = clinical frailty scale; mPG = mean pressure gradient; PPM = prosthesis-patient mismatch; PVL = paravalvular leakage; STS = Society of Thoracic Surgeons; other abbreviations as in Figure 1. Table 3PreMatched All-Cause MortalityUnivariable AnalysisMultivariable AnalysisHR95% CIP ValueHR95% CIP ValueAge1.0551.041-1.070<0.0011.0351.021-1.049<0.001Body mass index0.9270.910-0.944<0.0010.9920.977-1.0080.348Clinical frailty scale ≥41.6721.462-1.912<0.0011.1671.089-1.251<0.001NYHA functional class III or IV1.7531.546-1.988<0.0011.1911.115-1.272<0.001Diabetes mellitus1.0660.928-1.2250.368Atrial fibrillation1.4451.250-1.671<0.0011.1611.079-1.250<0.001Coronary artery disease1.0700.932-1.2280.338Peripheral artery disease1.5091.248-1.825<0.0011.1281.023-1.2430.015Previous stroke1.1970.980-1.460.078Chronic obstructive pulmonary disease1.3051.003-1.6980.0481.0980.961-1.2560.170STS score1.0100.999-1.0200.067Hemoglobin0.8080.774-0.843<0.0010.8520.815-0.891<0.001Left ventricular ejection fraction0.9880.983-0.993<0.0010.9990.994-1.0030.571Annulus area0.9990.998-1.0010.317Annulus perimeter1.0000.990-1.0110.955Self-expanding valve1.1981.046-1.3730.0091.0510.980-1.1270.165Severe prosthesis-patient mismatch1.2281.018-1.4820.0321.2661.048-1.5300.014Mean pressure gradient ≥20 mm Hg1.0450.827-1.3210.710Paravalvular leakage1.2081.057-1.3810.0061.0811.009-1.1580.027P values are from the Cox proportional hazards model.STS = Society of Thoracic Surgeons. PreMatched All-Cause Mortality P values are from the Cox proportional hazards model. STS = Society of Thoracic Surgeons. Discussion The key findings of the present study are as follows (Central Illustration). 1) In a cohort of women undergoing TAVR, in which 88% had a SAA, SEV demonstrated superior echocardiographic performance, including a larger EOA and lower mean PG, compared to BEV. These advantages were consistently observed over a 7-year follow-up period. 2) In the PSM cohort, HFH rates were comparable between the groups; however, the incidence of stroke and all-cause mortality was higher with SEV than with BEV. 3) In multivariable analysis, age, frailty, atrial fibrillation, peripheral artery disease, hemoglobin, severe PPM, and paravalvular leakage ≥ mild were identified as independent predictors of prognosis while the type of THV was not associated with long-term outcomes.Central IllustrationLong-Term Female Outcomes of Balloon-Expandable vs Self-Expanding Transcatheter Heart ValvesAS = aortic stenosis; BNP = brain natriuretic peptide; COPD = chronic obstructive pulmonary disease; OCEAN-TAVI = Optimized transCathEter vAlvular intervention-Transcatheter Aortic Valve Implantation; PAD = peripheral artery disease. Long-Term Female Outcomes of Balloon-Expandable vs Self-Expanding Transcatheter Heart Valves AS = aortic stenosis; BNP = brain natriuretic peptide; COPD = chronic obstructive pulmonary disease; OCEAN-TAVI = Optimized transCathEter vAlvular intervention-Transcatheter Aortic Valve Implantation; PAD = peripheral artery disease. In the era of expanding indications for TAVR toward a broader patient population, it is essential to maximize the benefits of TAVR. Consequently, clinical interest has been directed toward the differences in THV design, as echocardiographic parameters between BEV and SEV are particularly pronounced in women with SAA, heightening interest in their potential impact on long-term outcomes. This study demonstrated that, in women, SEV exhibited superior echocardiographic performance compared to BEV, with these differences persisting over a 7-year follow-up period. These findings align with prior short- and mid-term reports, indicating that SEV shows enhanced echocardiographic assessments relative to BEV for patients with a SAA, particularly in female patients.11,13,17, 18, 19 In this study, an elevated mean PG (≥20 mm Hg) was not associated with adverse outcomes. However, the BEV group had a higher prevalence of NYHA functional class III or IV at discharge than did the SEV group. Although our study did not focus on the impact on symptoms, there is a possibility that higher mean PG after TAVR was associated with this significant dyspnea in the BEV group. In addition, the shorter overall hospitalization period of the BEV group may have affected the remaining symptoms. In contrast, severe PPM defined by index EOA was identified as an independent predictor of prognosis, consistent with previous studies.10,17 Unlike previous studies in non-Asian countries (moderate PPM, 29.8%; severe PPM, 24.7%),18 even in the female-dominant cohort with a SAA, severe PPM was less frequently observed in this cohort (severe PPM, approximately 2%), presumably because of the smaller body surface area. This is one of the characteristics of the registry used in this study, and the extremely low incidence of severe PPM may be one reason why SEV failed to demonstrate a significant prognostic value despite its long-term advantage of valvular function over BEV. In contrast, paravalvular leakage was less frequent with BEV than with SEV, consistent with previous reports.15,19,20 BEV had a significantly lower grade of paravalvular leakage than did SEV immediately after TAVR, which is an advantage for BEV, although this difference diminished over time. Moreover, a previous study from our OCEAN-TAVI registry showed that the smallest size of SAPIEN (Edwards Lifesciences) valves demonstrated the advantage of less paravalvular leakage than did the other sizes of valves.21 These findings further support the observation from the forest plot analysis of interactions that BEV had significantly more interactions in patients with extremely small annuli (<362 mm2). In the PSM cohort of this study, BEV was associated with better outcomes compared with SEV in terms of all-cause mortality and stroke during a follow-up period of up to 7 years after TAVR. One reason for this is that the in-hospital outcomes for BEV were significantly better than those for SEV in terms of bleeding, stroke, and new pacemaker implantation. In this era where long-term outcomes are thought to be essential, it is necessary to provide reliable treatment that minimizes complications as much as possible in the short term. However, on the basis of other analytical results in this study and the characteristics of PSM, we should not overemphasize the PSM results alone. Although PSM was performed, residual selection bias cannot be excluded, as SEV was frequently chosen in patients with poor vascular access or severe annular calcification, raising concerns about higher risks of stroke and other complications.6,11 Even after implementing PSM, SEVs continued to have higher STS scores than did BEVs, making complete adjustment difficult. At this stage, we should emphasize the fact that we cannot exclude the possibility of chance or residual confounding. In addition to the fact that the significance of outcomes between BEV and SEV in PSM was small, multivariable analysis showed no significant association between THV type and prognosis. Despite SEV yielding favorable results in valve function, the lack of significant differences in prognosis in multivariable analysis is one point that should be emphasized as a finding of this study. Furthermore, in the subgroup analysis results presented in the forest plot, there was no difference in mortality between BEV and SEV even among patients with smaller aortic annulus structures, such as those with a SAA, annulus area < median, or annulus perimeter < median. Similarly, other subgroup analyses did not reveal any particular advantages of the THV type difference in improving prognosis. These results suggest that classical clinical factors, such as age, frailty, and traditional comorbidities, may outweigh anatomical or echocardiographic measurements in determining long-term outcomes. However, it should be noted that even with PSM, these background factors cannot be fully adjusted for and residual confounding factors cannot be ruled out. Regarding the reason why the significance of SEV’s advantage of valve function did not influence prognosis, we should consider that a cohort of patients with small body size and a low incidence of severe PPM—generally considered to affect prognosis—was small. Although BEV was associated with less favorable postoperative echocardiographic parameters, this does not necessarily preclude its selection in clinical practice, nor suggest that echocardiographic performance alone should dictate THV choice. In contrast, the observed trends in BEV outcomes for women, including those with a SAA, should be interpreted cautiously. Further studies with larger populations, longer follow-up, and inclusion of newer-generation devices are warranted to clarify the impact of THV type on prognosis and valvular performance. However, given that the indications of TAVR are expanding toward a broader population, this study had a significant impact by showing that both BEV and SEV provided favorable long-term performance for women with a SAA. Rather than the superiority of valve types, this patient-specific practice, considering the risk-benefit ratio, is essential. For example, in patients with a small annulus relative to their body size, it is important to implant SEV to avoid PPM, or in patients with right bundle branch block before TAVR, it is safe to implant BEV to avoid pacemaker implantation. These findings offer valuable insights into the ongoing debate on THV selection in patients with smaller anatomies.11,13,17, 18, 19 Furthermore, because the latest devices demonstrate even better hemodynamics than the older-type valves used in this study,11,22 research using the new types of valves will be of critical importance in the future. Study limitations This study has several limitations inherent to its design. It was based on observational, unblinded, and nonrandomized registry data, and so unmeasured variables may have influenced the results despite the use of PSM analysis. Considering that absolute standardized difference scores of STS score or other factors not included in adjustments exceeded 0.1, the high-risk group was more prevalent in the SEV group. It cannot be denied that these incomplete adjustments likely exacerbated the tendency toward worsened patient prognosis. Furthermore, missing values could not be completely excluded in this study, and there was a potential for selection bias, as older patients and high-risk patients are more likely to have missing data—a characteristic of clinical research. In particular, only 19.2% of patients could be followed up for examinations at 7 years after TAVI, raising concerns that this result may diminish the study’s validity. However, a strength of this study was the high-quality database achieved through rigorous querying at each center. Echocardiographic data were collected according to Valve Academic Research Consortium-3 criteria but were not adjudicated by an independent core laboratory. Post-TAVR, computed tomography data were unavailable, precluding detailed assessment of calcium scores. Moreover, because multivariable analysis did not identify THV type as an independent predictor of prognosis, the present findings cannot be interpreted as evidence that one valve type confers superior long-term outcomes over the other. Because patients treated with the latest THV devices were not included, this study could not assess potential improvements related to advances in device design or procedural technique.22, 23, 24 The cohort largely reflects the Japanese TAVR population, with a mean age of ∼85 years, so generalizability to younger, more active patients is limited. Nonetheless, the registry provided high-quality echocardiographic follow-up and a large sample size, allowing robust propensity score–matched comparisons. Last but not least, as shown in Figure 4, because BEV use remained higher than SEV use throughout the entire study period, it cannot be denied that the operator learning curve may have influenced postoperative outcomes. Conclusions This study focused exclusively on women undergoing TAVR, with 88% having a SAA. SEV demonstrated superior echocardiographic performance over 7-year follow-up, but these valve functional advantages did not translate into better clinical outcomes. In the PSM cohort, the long-term survival favored BEV over SEV; however, multivariable analysis revealed no independent prognostic association with valve type. In the era of expanding indications of TAVR toward a broader population, this study had a significant impact by showing that both BEV and SEV provided favorable long-term performance for women predominantly presenting with a SAA, when implanting valves based on individual patient risk-benefit considerations. Funding Support and Author Disclosures The OCEAN-TAVI registry was supported by Edwards Life Sciences, Medtronic, Boston Scientific, Abbott, and Daiichi-Sankyo, Japan. Drs Tsuruta and Izumo are screening proctors for Edwards Lifesciences. Dr Shimizu is a clinical proctor for Edwards Lifesciences. Drs Yashima and Nishina are clinical proctors for Medtronic. Drs Asami and Ohno are clinical proctors for Medtronic and Abbott. Dr Shimura is a clinical proctor for Abbott. Dr Ishizu is a proctor for intracardiac echocardiography for Johnson & Johnson. Dr Fuku is a clinical proctor for Edwards Lifesciences and Medtronic. Drs Yamamoto, Shirai, Watanabe, Naganuma, and Hayashida are clinical proctors for Edwards Lifesciences, Abbott, and Medtronic. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.